|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1993-6-18
|
|
pubmed:abstractText |
Widely disseminated neuroblastoma in children older than infancy remains a very poor prognosis disease. Even the introduction of marrow ablative chemotherapy with autologous rescue has not significantly improved the outlook for these children, presumably because of a failure to eradicate minimal residual disease. One additional approach which may hold promise is the use of immunomodulation with cytokines such as IL2 in the setting of minimal residual disease (MDR), for example after intensive chemotherapy and ABMT. However, considerable variability in the susceptibility of neuroblastoma cells to natural killer (NK) and lymphokine-activated (LAK) killing has been observed, and it is presently unclear how NK and LAK cells recognise neuroblastoma cells. In this paper we examine expression of cell adhesion molecules on neuroblastoma to determine which of these modify interaction with NK and LAK cells. We find that LFA-3 (CD58), the ligand for CD2 is of predominant importance in predicting susceptibility of neuroblastoma to the cytotoxic actions of NK and LAK cells, while expression of ICAM-1 (CD54) may also modify susceptibility. These findings were confirmed by blocking experiments in which co-culture of target cells with ICAM-1 and LFA-3 reduced LAK and NK cytotoxicity. Study of the immunophenotypic features of each patient's neuroblastoma cells before induction of MRD may be valuable in determining the likely effect of IL2 in predicting disease reactivation.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-1701347,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-1708296,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-1710608,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-1712495,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-1830096,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-1972538,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-1973061,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-1975567,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-1985165,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-2033418,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-2033426,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-2066755,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-2482743,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-2492800,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-2495037,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-2641703,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-2787201,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-3028646,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-3043452,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-3102676,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-3158702,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-3275493,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-3340213,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-4102970,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-7037033,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8494726-7247438
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
933-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:8494726-Cell Adhesion Molecules,
pubmed-meshheading:8494726-Child,
pubmed-meshheading:8494726-Cytotoxicity, Immunologic,
pubmed-meshheading:8494726-Humans,
pubmed-meshheading:8494726-Immunity, Cellular,
pubmed-meshheading:8494726-Immunophenotyping,
pubmed-meshheading:8494726-Immunotherapy,
pubmed-meshheading:8494726-Killer Cells, Lymphokine-Activated,
pubmed-meshheading:8494726-Killer Cells, Natural,
pubmed-meshheading:8494726-Neuroblastoma,
pubmed-meshheading:8494726-Tumor Cells, Cultured
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication.
|
|
pubmed:affiliation |
Department of Hematology/Oncology, St Jude Children's Research Hospital, Memphis, Tennessee 38105.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
